Sign In

Login

Password

Forgot Password ? Sign Up

Vandetanib (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vandetanib" in German language version.

refsWebsite
Global rank German rank
5doi.org
2nd place
3rd place
5nih.gov
4th place
7th place
3europa.eu
68th place
29th place
1web.archive.org
1st place
1st place
1redirecter.toolforge.org
33rd place
2nd place
1cancer.gov
1,684th place
7,111th place
1drugs.com
399th place
3,700th place
1bloomberg.com
99th place
323rd place
1pmlive.com
low place
low place
1genengnews.com
low place
low place
1fda.gov
447th place
751st place
1aacrjournals.org
8,869th place
5,334th place
1bfarm.de
low place
1,217th place

aacrjournals.org

cancerres.aacrjournals.org

  • Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora: ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases. In: Cancer Research. Band 62, Nr. 24, 15. Dezember 2002, S. 7284–7290, PMID 12499271 (englisch, aacrjournals.org [abgerufen am 19. Februar 2021]).

bfarm.de

bloomberg.com

  • Sanofi to Buy Caprelsa Drug from AstraZeneca for $300 Million. In: Bloomberg.com. 27. Juli 2015 (englisch, bloomberg.com [abgerufen am 19. Februar 2021]).

cancer.gov

  • vandetanib. 2. Februar 2011, abgerufen am 19. Februar 2021 (englisch).

doi.org

  • David Viola, Laura Valerio, Eleonora Molinaro, Laura Agate, Valeria Bottici: Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. In: Endocrine-Related Cancer. Band 23, Nr. 4, 1. April 2016, S. R185–R205, doi:10.1530/ERC-15-0555.
  • Gary Middleton et al.: Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. In: The Lancet Oncology. Band 18, 2017, S. 486–499, doi:10.1016/S1470-2045(17)30084-0.
  • Paul Martin, Stuart Oliver, Sarah-Jane Kennedy, Elizabeth Partridge, Michael Hutchison: Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. In: Clinical Therapeutics. Band 34, Nr. 1, Januar 2012, S. 221–237, doi:10.1016/j.clinthera.2011.11.011, PMID 22206795.
  • Varun Khurana, Mukul Minocha, Dhananjay Pal, Ashim K. Mitra: Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. In: Drug metabolism and drug interactions. Band 29, Nr. 3, 2014, S. 179–190, doi:10.1515/dmdi-2013-0062, PMID 24643910, PMC 4407685 (freier Volltext).
  • Varun Khurana, Mukul Minocha, Dhananjay Pal, Ashim K. Mitra: Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. In: Drug metabolism and drug interactions. Band 29, Nr. 4, 2014, S. 249–259, doi:10.1515/dmdi-2014-0014, PMID 24807167, PMC 4407688 (freier Volltext) – (englisch).

drugs.com

europa.eu

ema.europa.eu

echa.europa.eu

fda.gov

accessdata.fda.gov

genengnews.com

nih.gov

ncbi.nlm.nih.gov

  • Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora: ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases. In: Cancer Research. Band 62, Nr. 24, 15. Dezember 2002, S. 7284–7290, PMID 12499271 (englisch, aacrjournals.org [abgerufen am 19. Februar 2021]).
  • Paul Martin, Stuart Oliver, Sarah-Jane Kennedy, Elizabeth Partridge, Michael Hutchison: Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. In: Clinical Therapeutics. Band 34, Nr. 1, Januar 2012, S. 221–237, doi:10.1016/j.clinthera.2011.11.011, PMID 22206795.
  • Varun Khurana, Mukul Minocha, Dhananjay Pal, Ashim K. Mitra: Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. In: Drug metabolism and drug interactions. Band 29, Nr. 3, 2014, S. 179–190, doi:10.1515/dmdi-2013-0062, PMID 24643910, PMC 4407685 (freier Volltext).
  • Varun Khurana, Mukul Minocha, Dhananjay Pal, Ashim K. Mitra: Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. In: Drug metabolism and drug interactions. Band 29, Nr. 4, 2014, S. 249–259, doi:10.1515/dmdi-2014-0014, PMID 24807167, PMC 4407688 (freier Volltext) – (englisch).

dailymed.nlm.nih.gov

pmlive.com

redirecter.toolforge.org

  • Caprelsa 100 mg & 300 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc). Archiviert vom Original (nicht mehr online verfügbar) am 28. Februar 2017; abgerufen am 19. Februar 2021 (englisch).

web.archive.org

  • Caprelsa 100 mg & 300 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc). Archiviert vom Original (nicht mehr online verfügbar) am 28. Februar 2017; abgerufen am 19. Februar 2021 (englisch).